Tiagabine inhibits haloperidol-induced oral dyskinesias in rats

X. M. Gao, T. Kakigi, M. B. Friedman, C. A. Tamminga

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Chronic administration of haloperidol to male Sprague Dawley rats for 6 months at a dosage of 1.5 mg/kg/day produces oral dyskinesias in a significant percent of the treated group. This has been used as an animal model of tardive dyskinesia in several laboratories, because the rat movements display characteristics reminiscent of the human dyskinetic condition. Previously, we have reported a reduction in these haloperidol-induced oral dyskinesias with the coadministration of a direct acting GABA agonist progabide. Here, we have tested an indirect acting GABA agonist, tiagabine, coadministered with haloperidol, for its effect on the oral dyskinesias. At a dosage of 75 mg/kg/day tiagabine significantly inhibited the onset of vacuous chewing movements (VCMs), decreasing the average movement severity from 11.2 ± 2.0 to 4.4 ± 1.4, compared with a placebo rate of 1.3 ± 0.5 (VCMs/5 min). These data support the proposition that an effective, potent GABAmimetic coadministered with haloperidol, will block the onset of rat oral dyskinesias. This conclusion has important implications for the treatment and prevention of tardive dyskinesia in humans.

Original languageEnglish (US)
Pages (from-to)63-69
Number of pages7
JournalJournal of Neural Transmission
Volume95
Issue number1
DOIs
StatePublished - Feb 1994

Fingerprint

Movement Disorders
Haloperidol
GABA Agonists
Mastication
Sprague Dawley Rats
Animal Models
Placebos
tiagabine
Tardive Dyskinesia
Therapeutics

Keywords

  • GABAmimetic
  • haloperidol
  • Tardive dyskinesia
  • tiagabine

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Tiagabine inhibits haloperidol-induced oral dyskinesias in rats. / Gao, X. M.; Kakigi, T.; Friedman, M. B.; Tamminga, C. A.

In: Journal of Neural Transmission, Vol. 95, No. 1, 02.1994, p. 63-69.

Research output: Contribution to journalArticle

Gao, X. M. ; Kakigi, T. ; Friedman, M. B. ; Tamminga, C. A. / Tiagabine inhibits haloperidol-induced oral dyskinesias in rats. In: Journal of Neural Transmission. 1994 ; Vol. 95, No. 1. pp. 63-69.
@article{73ca0f85e9d640b3844a210c3bb94d09,
title = "Tiagabine inhibits haloperidol-induced oral dyskinesias in rats",
abstract = "Chronic administration of haloperidol to male Sprague Dawley rats for 6 months at a dosage of 1.5 mg/kg/day produces oral dyskinesias in a significant percent of the treated group. This has been used as an animal model of tardive dyskinesia in several laboratories, because the rat movements display characteristics reminiscent of the human dyskinetic condition. Previously, we have reported a reduction in these haloperidol-induced oral dyskinesias with the coadministration of a direct acting GABA agonist progabide. Here, we have tested an indirect acting GABA agonist, tiagabine, coadministered with haloperidol, for its effect on the oral dyskinesias. At a dosage of 75 mg/kg/day tiagabine significantly inhibited the onset of vacuous chewing movements (VCMs), decreasing the average movement severity from 11.2 ± 2.0 to 4.4 ± 1.4, compared with a placebo rate of 1.3 ± 0.5 (VCMs/5 min). These data support the proposition that an effective, potent GABAmimetic coadministered with haloperidol, will block the onset of rat oral dyskinesias. This conclusion has important implications for the treatment and prevention of tardive dyskinesia in humans.",
keywords = "GABAmimetic, haloperidol, Tardive dyskinesia, tiagabine",
author = "Gao, {X. M.} and T. Kakigi and Friedman, {M. B.} and Tamminga, {C. A.}",
year = "1994",
month = "2",
doi = "10.1007/BF01283031",
language = "English (US)",
volume = "95",
pages = "63--69",
journal = "Journal of Neural Transmission",
issn = "0300-9564",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Tiagabine inhibits haloperidol-induced oral dyskinesias in rats

AU - Gao, X. M.

AU - Kakigi, T.

AU - Friedman, M. B.

AU - Tamminga, C. A.

PY - 1994/2

Y1 - 1994/2

N2 - Chronic administration of haloperidol to male Sprague Dawley rats for 6 months at a dosage of 1.5 mg/kg/day produces oral dyskinesias in a significant percent of the treated group. This has been used as an animal model of tardive dyskinesia in several laboratories, because the rat movements display characteristics reminiscent of the human dyskinetic condition. Previously, we have reported a reduction in these haloperidol-induced oral dyskinesias with the coadministration of a direct acting GABA agonist progabide. Here, we have tested an indirect acting GABA agonist, tiagabine, coadministered with haloperidol, for its effect on the oral dyskinesias. At a dosage of 75 mg/kg/day tiagabine significantly inhibited the onset of vacuous chewing movements (VCMs), decreasing the average movement severity from 11.2 ± 2.0 to 4.4 ± 1.4, compared with a placebo rate of 1.3 ± 0.5 (VCMs/5 min). These data support the proposition that an effective, potent GABAmimetic coadministered with haloperidol, will block the onset of rat oral dyskinesias. This conclusion has important implications for the treatment and prevention of tardive dyskinesia in humans.

AB - Chronic administration of haloperidol to male Sprague Dawley rats for 6 months at a dosage of 1.5 mg/kg/day produces oral dyskinesias in a significant percent of the treated group. This has been used as an animal model of tardive dyskinesia in several laboratories, because the rat movements display characteristics reminiscent of the human dyskinetic condition. Previously, we have reported a reduction in these haloperidol-induced oral dyskinesias with the coadministration of a direct acting GABA agonist progabide. Here, we have tested an indirect acting GABA agonist, tiagabine, coadministered with haloperidol, for its effect on the oral dyskinesias. At a dosage of 75 mg/kg/day tiagabine significantly inhibited the onset of vacuous chewing movements (VCMs), decreasing the average movement severity from 11.2 ± 2.0 to 4.4 ± 1.4, compared with a placebo rate of 1.3 ± 0.5 (VCMs/5 min). These data support the proposition that an effective, potent GABAmimetic coadministered with haloperidol, will block the onset of rat oral dyskinesias. This conclusion has important implications for the treatment and prevention of tardive dyskinesia in humans.

KW - GABAmimetic

KW - haloperidol

KW - Tardive dyskinesia

KW - tiagabine

UR - http://www.scopus.com/inward/record.url?scp=0028179598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028179598&partnerID=8YFLogxK

U2 - 10.1007/BF01283031

DO - 10.1007/BF01283031

M3 - Article

C2 - 7857587

AN - SCOPUS:0028179598

VL - 95

SP - 63

EP - 69

JO - Journal of Neural Transmission

JF - Journal of Neural Transmission

SN - 0300-9564

IS - 1

ER -